HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, K. J. Search for Related Content PubMed PubMed Citation Articles by Miller, K. J.

SEROTONIN 5-HT_2C RECEPTOR AGONISTS: POTENTIAL FOR THE TREATMENT OF OBESITY

Metabolic Diseases Research, HPW 21-2.03, Discovery Biology P.O. Box 5400, Princeton, NJ 08543-5400

Obesity continues to be a burgeoning health problem worldwide. Before their removal from the market, fenfluramine and the more active enantiomer dexfenfluramine were considered to be among the most effective of weight loss agents. Much of the weight loss produced by fenfluramine was attributed to the direct activation of serotonin 5-HT_2C receptors in the central nervous system via the desmethyl-metabolite of fenfluramine, norfenfluramine. Norfenfluramine, however, is non-selective, activating additional serotonin receptors, such as 5-HT_2A and 5-HT_2B, which likely mediated the heart valve hypertrophy seen in many patients. Development of highly selective 5-HT_2C agonists may recapitulate the clinical anti-obesity properties observed with fenfluramine while avoiding the significant cardiovascular and pulmonary side effects.

This article has been cited by other articles:

				W. J. Thomsen, A. J. Grottick, F. Menzaghi, H. Reyes-Saldana, S. Espitia, D. Yuskin, K. Whelan, M. Martin, M. Morgan, W. Chen, et al. Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 577 - 587. [Abstract] [Full Text] [PDF]

				M. Desai, D. Gayle, G. Han, and M. G. Ross Programmed Hyperphagia Due to Reduced Anorexigenic Mechanisms in Intrauterine Growth-Restricted Offspring Reproductive Sciences, May 1, 2007; 14(4): 329 - 337. [Abstract] [PDF]